CTXR Profile
Citius Pharmaceuticals, Inc., based in Cranford, New Jersey, is a late-stage biopharmaceutical company focused on developing and commercializing critical care products. The company’s portfolio is primarily concentrated on oncology, anti-infectives for adjunct cancer care, prescription products, and stem cell therapies. Citius Pharmaceuticals is advancing a range of proprietary products designed to address significant unmet medical needs in critical care and oncology.
One of its leading candidates is I/ONTAK, an engineered fusion protein combining interleukin-2 (IL-2) with diphtheria toxin. This innovative therapy is aimed at treating patients with persistent or recurrent cutaneous T-cell lymphoma, a rare and challenging form of cancer. The company is also developing Mino-Lok, an antibiotic lock solution intended to treat catheter-related bloodstream infections by salvaging infected catheters, thereby potentially reducing the need for catheter replacement and associated complications.
Another key product in development is Halo-Lido, a topical formulation combining corticosteroids and lidocaine. This product aims to offer both anti-inflammatory and anesthetic relief for patients suffering from hemorrhoids, addressing a common and often painful condition with a dual-action approach. Additionally, Citius is working on Mino-Wrap, a gel-based wrap designed to reduce the incidence of infections associated with tissue expanders used in breast reconstructive surgeries.
The company’s stem cell therapy, NoveCite, represents its foray into regenerative medicine. This mesenchymal stem cell therapy is being investigated for its potential to treat acute respiratory distress syndrome (ARDS), a severe and often life-threatening condition. Founded in 2007, Citius Pharmaceuticals continues to drive innovation in critical care and oncology, with a strategic focus on bringing transformative therapies to market.
|
